glp-1 ncbi Glucagon-like peptide-1 receptor: mechanisms and advances in therapy GLP-1 actions and target organs.

However, he recommends referring to the manufacturers instructions, as some brands may have shorter or longer storage times

Glucagon-Like 1 Receptor Agonist Use Was Associated With Improved Outcomes In Patients With Inflammatory Bowel Disease: A Large Real-World Database Study

Encapsulation of exenatide in poly-(D, L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes

Klein H, et al

Retatrutide adds glucagon for 28.7%

Innovations introduced longer-acting formulations: semaglutide (novel peptide with fatty acid modifications) enabled once-weekly dosing and was first approved as Ozempic (T2D, 2017) and then as Wegovy (obesity, 2021)